PRKAA2 and central nervous system cancer: Recently, we found that SR4 dose-dependently activates AMPK in various types of human and animal cancer cell lines (leukemia, lung, pancreatic, liver, ovarian, melanoma, glioma, breast) (unpublished data), as well as 3T3-LI adipocytes [27].